Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
- Revenue in EUR (TTM)3.58bn
- Net income in EUR1.11bn
- Incorporated2008
- Employees1.60k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qiagen NV | 1.80bn | 365.86m | 8.44bn | 5.65k | 23.83 | 2.73 | 15.85 | 4.69 | 1.72 | 1.72 | 8.44 | 15.02 | 0.3488 | 2.66 | 5.45 | 318,305.30 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| Eurofins Scientific SE | 6.76bn | 662.20m | 12.04bn | 65.69k | 18.62 | 2.57 | 8.89 | 1.78 | 3.55 | 2.20 | 36.23 | 25.71 | 0.6177 | 36.38 | 4.79 | 102,842.00 | 6.63 | 7.27 | 8.41 | 9.08 | 24.29 | 23.69 | 10.74 | 11.01 | 1.03 | 8.55 | 0.492 | 23.70 | -2.80 | 4.43 | 4.37 | -0.2934 | 8.58 | 1.15 |
| Genmab A/S | 3.20bn | 829.02m | 15.29bn | 3.03k | 17.92 | 2.91 | 17.17 | 4.77 | 99.21 | 99.21 | 381.20 | 610.43 | 0.3858 | 17.63 | 3.66 | 7,900,671.00 | 9.99 | 14.22 | 11.25 | 15.57 | 93.60 | 96.72 | 25.89 | 31.44 | 2.01 | -- | 0.4813 | -- | 19.19 | 19.19 | -15.00 | 5.77 | 3.22 | -- |
| Lonza Group AG | 7.19bn | 1.00bn | 40.08bn | 19.77k | 40.04 | 3.89 | 23.39 | 5.57 | 12.94 | 13.51 | 93.02 | 133.07 | 0.3375 | 2.45 | 4.32 | 330,332.30 | 4.70 | 4.70 | 5.78 | 5.72 | 36.15 | 37.28 | 13.92 | 13.02 | 1.77 | 7.77 | 0.313 | 34.17 | -0.6541 | 7.70 | 42.92 | 4.48 | 7.13 | 10.76 |
| argenx SE | 3.58bn | 1.11bn | 40.13bn | 1.60k | 38.58 | -- | -- | 11.22 | 16.81 | 16.81 | 54.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 89.15 | -- | 31.12 | 8.40 | -- | -- | -- | -- | 89.54 | 151.52 | 55.10 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.30m | 3.71% |
| Wellington Management Co. LLPas of 24 Jun 2024 | 1.82m | 2.94% |
| Norges Bank Investment Managementas of 06 Jan 2026 | 1.74m | 2.81% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.21m | 1.96% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 941.17k | 1.52% |
| Amundi Asset Management SASU (Investment Management)as of 25 Feb 2026 | 847.54k | 1.37% |
| Geode Capital Management LLCas of 26 Feb 2026 | 707.76k | 1.14% |
| Schroder Investment Management Ltd.as of 31 Jan 2026 | 561.10k | 0.91% |
| Bellevue Asset Management AGas of 30 Jan 2026 | 543.61k | 0.88% |
| Fidelity Management & Research Co. LLCas of 05 Feb 2026 | 443.79k | 0.72% |
